Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC 1| WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé.
Download ReportTranscript Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC 1| WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé.
Good Governance for Medicines Programme
Dr Cécile Macé EMP/MPC 1 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Unethical practices can be found throughout medicines chain
R&D and clinical trials Patent R&D priorities 2 | Cartels Manufacturing Registration Unethical donations Pricing Selection Collusion Conflict of interest Procurement & import Counterfeit/ substandard Distribution Inspection Pressure Thefts Tax evasion Over invoicing Falsification safety/ efficacy data Prescription Bribery State Capture Dispensing Pharmacovigilance Unethical promotion Promotion WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Why a Good Governance for Medicines Programme?
To improve transparency, accountability, effective, efficient and ethical management of pharmaceutical systems To improve the health service delivery to the population in countries through improved access to quality-assured medicines and rational use To avoid wastage or misuse of public or donor funding in the pharmaceutical sector To improve public trust and confidence on health system To support countries to identify, prioritize and mitigate risks To develop guidance to support countries in improving good governance in the pharmaceutical system
3 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
WHO Good Governance for Medicines Programme:
Goal – To contribute to health systems strengthening and to prevent corruption by promoting good governance in the pharmaceutical sector Specific objectives – To raise awareness on the impact of corruption in the pharmaceutical sector and bring this to the national health policy agenda – To increase transparency and accountability in medicine regulatory and supply management systems – To promote individual and institutional integrity in the pharmaceutical sector – To institutionalize good governance in pharmaceutical systems by building national capacity and leadership
4 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
5 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Good Governance for Medicines
programme:
a model process
Clearance MOH PHASE I National transparency assessment Assessment report PHASE II Development national GGM framework GGM framework officially adopted PHASE III Implementation national GGM programme GGM integrated in MOH plan 6 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Achievements in countries
Increased awareness of impact of corruption in the Pharmaceutical Sector and Importance of having Good Governance and Transparency
1.
National Assessments done and published 2.
GGM incorporated in National Health Agenda by nominating a task force and steering committee to work on framework 3.
Increase in political will to implement GGM 4.
Collaboration between various stakeholders (MoH, other ministries, anti corruption commission, NGOs, private sector …)
7 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Achievements in countries
Increased Transparency and Accountability in Medicine Regulatory and Supply Systems
1.
Various laws, regulations, SOPs created or reviewed/updated 2.
Management of conflicts of interest put in place for various committees 3.
Information publicly available to increase transparency 4.
Whistle-blower protection bill passed, increase in number of corruption cases investigated 5.
Increased accessibility of medicines at lower costs 6.
Appeal mechanism put in place
8 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Achievements in countries
Increased promotion of individual and institutional integrity in the pharmaceutical sector
1.
National GGM Framework developed, adopted and published 2.
Creation of Code of conduct for people working in the public pharmaceutical sector 3.
Continuous training workshops on ethical leadership and GGM at national and regional level 4.
Continuous collaboration with other stakeholders 5.
GGM included in the curricula of phamacy students
9 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Achievements in countries
Institutionalization of GGM
1.
In Mongolia, the MoH has designated by law in 2010 the Drug Regulatory Agency to implement GGM 2.
In Philippines, the GGM team in the MoH is having a specific budget to conduct activities 3.
Still in progress in other countries …
10 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Common challenges faced in implementation
Cultural and behavioural: resistance to change, passive attitude or tolerance Political: instability, change in government Managerial: lack staff, rotation, lack of financial resources Structural: more difficult if basic systems not in place Technical: integration in day to day affairs, new subject, access to legislation documents Time: workload, other priorities; GGM not a priority
11 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Key observations and lessons learnt
1.
Great interest in subject area 2.
A dedicated and motivated national team to tackle the issue 3.
Involvement of high-level and technical officials essential 4.
Collaboration with key stakeholders 5.
Promotion of integrity together with legislative reforms 6.
Timeframe different between countries 7.
Institutionalization needed for sustainability
12 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012
Thank you!
http://www.who.int/medicines/ggm/en/index.html
13 | WHO-Technical Briefing Seminar
Dr Cécile Macé
|
October-November 2012